Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenoten for children in infants with sequelae of perinatal brain injury
NCT03159611Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Feb 2016
- Primary completion
- Feb 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Perinatal brain injury comparing Tenoten for children with Placebo (2 arms). Primary endpoint: Percentage of Patients With a 4 and More Point Increase of the Total Score According to Jurba-Mastyukova Psychomotor Development Scale at 12 weeks. Started Feb 2016; status: completed.
02
Drugs
Tenoten
03
Conditions
Perinatal brain injury
Beyond the preview
Go deeper on NCT03159611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159611.